DOCSLIB.ORG

Active Topoisomerase II in Patients with Leukaemia J Clin Pathol: First Published As 10.1136/Jcp.49.10.848 on 1 October 1996

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Active Topoisomerase II in Patients with Leukaemia J Clin Pathol: First Published As 10.1136/Jcp.49.10.848 on 1 October 1996 8488 Clin Pathol 1996;49:848-852 Method for quantifying expression of functionally active topoisomerase II in patients with leukaemia J Clin Pathol: first published as 10.1136/jcp.49.10.848 on 1 October 1996. Downloaded from A R Cattan, D Levett, E A Douglas, P G Middleton, P R A Taylor Abstract phenotype in vivo of the eventual failure of Aims-To produce a method to measure response to treatment seen in patients with and quantify enzymatically active topo- leukaemia.6 isomerase II in normal and neoplastic The topoisomerases are a ubiquitous family human cells. ofenzymes seen in bacteria (DNA gyrases) and Methods-A crude cell lysate from density in eukaryote organisms where two major forms separated mononuclear cells from either exist: topoisomerase I which catalyse single peripherial blood or bone marrow was strand DNA breaks and ligations; and topo- prepared as a source of topoisomerases. isomerase II which catalyse the cleavage and Using the lysate, minicircles from the ligation of double strand DNA breaks. These Crithedia kinetoplast DNA complex were enzymes are believed to play important roles in decatenated before being separated by DNA replication, repair and in gene transcrip- agarose gel electrophoresis and visualised tion (for review see 7 8). In mammalian cells using ethidium bromide/ultraviolet fluor- there are two forms (a and [) oftopoisomerase escence. II.9 Little is still known about their explicit Results-Cell number, sample volume roles although there are reported associations and drug inhibition concentration re- with the cell cycle'0 and changes in expression quired to produce reliable and reproduc- of the two forms in cell lines under cytotoxic ible assay conditions were established. drug selection."1 Intra- and interassay standards were A variety of drugs used in the treatment of included which permitted the quantifica- leukaemia, including the anthracyclines (dau- tion of active topoisomerase II in matched norubicin, idarubicin), epipodophyllotoxins peripheral blood, bone marrow, presenta- (VP-16) and anthraquinone (mitoxantrone), tion, and relapse samples from patients are known to target topoisomerase II, and may with acute lymphoblastic leukaemia. Ac- be partly responsible for the antineoplastic tive topoisomerase II has been converted effects found. Attempts to measure activities of to a unit scale which has been used to topoisomerase II and changes in their proper- compare topoisomerase II activities in ties in mammalian cellular preparations have cells from patients with normal blood and been largely restricted to cell lines.'2-14 Topo- http://jcp.bmj.com/ bone marrow samples. isomerase II activities in clinical leukaemic Conclusions-There was no change in samples have been reported using slot blots to topoisomerase II activities between sam- detect specific mRNAs'5 16 and by western blot- ples taken at presentation and those taken ting to detect protein and determine protein during a recurrence. However, topoisom- concentrations.'6 17 As topoisomerase II expres- erase II activity in leukaemic blast popula- sion has been shown to be decreased in cell tions was increased compared with lines exposed to cytotoxic agents,'7 18 several on October 2, 2021 by guest. Protected copyright. topoisomerase II activity in normal cells. groups have attempted to show a similar corre- (7 Clin Pathol 1996;49:848-852) lation in clinical specimens with the hope of relating this to clinical outcome. Although it Keywords: drug resistance, topoisomerases, leukaemia. has been reported that topoisomerase II expression changes during treatment, most investigations have been unable to correlate At presentation, most acute leukaemias show this expression with remission status.'5-'` Ellis some response to treatment; however, with et all9 have described a filter based assay to time most adult patients succumb to their dis- quantify biologically active topoisomerase II in ease due to relapse. Following relapse, treat- a cell line with the intention of using this ment protocols become less effective and drug method in an attempt to predict the develop- concentrations are escalated with the addition ment of drug resistance to the topoisomerases. of other chemotherapeutic agents. This phe- Quantification of topoisomerase II by either Department of nomenon of failing response to therapy with measurement of mRNA or specific protein and Haematology, increased tumour load is often referred to col- the use of this to correlate topoisomerase II University of lectively as the development of drug resistance. activity with drug resistance phenotype does Newcastle upon Tyne, There are many in vitro and in vivo models not take into account that the protein may be Royal Victoria Infirmary, Newcastle used to describe the development of drug non-functional. It is known that phosphoryla- upon Tyne NEI 4LP resistance, including the multidrug resistance tion status affects topoisomerase II function phenotype or MDR,' drug detoxification,' and that this may alter the antineoplastic effect Correspondence to: changes in both the level and structure of the of the drugs in question.8 In an attempt to Dr A R Cattan. drug target,3 and changes in DNA repair address this problem, we have developed an Accepted for publication mechanisms.4 All of these mechanisms may assay to measure biologically active topo- 16 July 1996 work alone or in concert to produce the isomerase II in leukaemic samples. We report Topoisomerase II in leukaemia 849 Table 1 Patient details PREPARATION OF CRITHEDIA DNA Crithedia fasciculata (a gift of Dr I Hickson, Patient Age Sex Diagnosis Presenting Remission status Anti-leukaemic chemotherapy given Oxford) was grown in brain heart infusion number phenotype WBC x achieved prior to sample J Clin Pathol: first published as 10.1136/jcp.49.10.848 on 1 October 1996. Downloaded from 109/l medium (Difco) containing 10 ig/ml hemin, Control 73 M B-CLL Chlorambucil (832 mg), 100 gg/ml penicillin, 0.125 ,ug/ml streptomycin prednisolone (520 mg) at 280C to 1-5 x 107/ml. DNA was prepared ALL1 23 F Calla+ 190 Complete Induction therapy + intensive from the harvested protozoa (2 x 10") using ALL remission therapy + consolidation + allograft ALL2 48 M T-ALL 357 Complete Induction therapy + intensive standard lysis and chloroform/alcohol extrac- remission therapy + consolidation + allograft tion methods. The mixture of genomic and ALL3 39 M preB-ALL 63.3 Complete Induction therapy + intensive kinetoplast DNA was treated with RNase A remission therapy + consolidation + allograft ALL4 16 M Calla+ 44.2 No remission Induction therapy + intensive (bovine pancreas; Sigma, Poole, Dorset, UK) ALL therapy for 60 minutes at 37°C (50 jg/ml final concen- ALL5 62 F B-ALL 19.4 No remission None tration) and then mixed with molecular weight ALL6 16 M Null 44.8 No remission None ALL marker (5:3 ratio Hind III digested bacterio- ALL7 21 M Calla+ 13.7 No remission None phage k markers; Integra Biosciences) to form ALL the target DNA for the topoisomerase II assay. ALL8 47 F Null 43.4 Complete None ALL remission ALL9 * 42 F preB-ALL 63.7 Complete None ASSAY OF TOPOISOMERASE II ACTIVITY remission The assay is an adaption of the assay of Davies *Leukaemia secondary to treatment for Hodgkin's disease; WBC = white blood cell. et al.22 Briefly, 5 gl reaction buffer (50 mM Tris (pH 7.9), 120 mM KCI, 10 mM MgCl2, 0.5 the characterisation of this assay and the mM EDTA, 30 gg/ml bovine serum albumin, 5 expression of functional topoisomerase II in mM DTT, 5 mM ATP), 5 ,ul adriamycin (380 leukaemic blasts taken from patients with acute ng/ml in water), 24.5 gl water, 7.5 pl cell lysate, lymphoblastic leukaemia (ALL). and 8 gl Crithedialk DNA phage were mixed in a microcentrifuge tube, incubated at 30°C for Methods 30 minutes and the reaction stopped by the PATIENTS addition of 12.5 jtl stop solution (5% w/v SDS, The diagnosis of leukaemia was made by a 30% glycerol, 2.5 jtg bromophenol blue). consultant haematologist using Romanovsky stained blood and marrow smears and was PROTEIN ESTIMATION confirmed by appropriate cytochemical stain- Protein content in lysates was measured ing and immunophenotyping of the leukaemic according to the method of Bradford,23 blasts. Details of the patients at presentation adapted for use on a 96 well plate reader (Mul- are shown in table 1. All cases were of de novo tiskan MCC 340). leukaemia except for patient ALL9 where the leukaemia was considered secondary to previ- GEL ELECTROPHORESIS AND DENSITOMETRIC ous chemotherapy for Hodgkin's disease. All MEASUREMENTS patients received initial chemotherapy accord- Assay samples were run for 16 hours in 0.8% http://jcp.bmj.com/ ing to the NEALL III Protocol.20 Remission (w/v) agarose using standard DNA electro- induction therapy was with vincristine, pred- phoresis conditions and bands visualised with nisolone, adriamycin, and cytosine. If complete ethidium bromide. Following electrophoresis remission (defined as <5% blasts in an the resulting separations of DNA molecules adequately cellular marrow) was not achieved were visualised by ultraviolet illumination of by seven weeks, then further intensive treat- the DNA-ethidium complexes (302 nm trans- ment with high dose cytosine and mito- illumination) and the image stored electroni- on October 2, 2021 by guest. Protected copyright. xantrone was given. Four patients did not cally for further analysis (UVP 2000, Ultaviolet achieve complete remission. Two patients had Products Ltd). The units of topoisomerase II recognised adverse factors (ALL6, Ph chromo- were calculated by adjusting the ratio of the some positive; ALL7, B-ALL) and a third total area of topoisomerase II to k marker (ALL8) evolved to acute myeloid leukaemia bands to those produced by an aliquoted con- after five weeks on treatment. Consolidation trol lysate in that particular test and corrected treatment was with vincristine, steroids, cyto- to the relevant point on a standard curve (fig sine, asparaginase, methotrexate, and 6-thio- 1).
Load more

Recommended publications
  • B Number Gene Name Mrna Intensity Mrna
    sample) total list predicted B number Gene name assignment mRNA present mRNA intensity Gene description Protein detected - Membrane protein membrane sample detected (total list) Proteins detected - Functional category # of tryptic peptides # of tryptic peptides # of tryptic peptides detected (membrane b0002 thrA 13624 P 39 P 18 P(m) 2 aspartokinase I, homoserine dehydrogenase I Metabolism of small molecules b0003 thrB 6781 P 9 P 3 0 homoserine kinase Metabolism of small molecules b0004 thrC 15039 P 18 P 10 0 threonine synthase Metabolism of small molecules b0008 talB 20561 P 20 P 13 0 transaldolase B Metabolism of small molecules chaperone Hsp70; DNA biosynthesis; autoregulated heat shock b0014 dnaK 13283 P 32 P 23 0 proteins Cell processes b0015 dnaJ 4492 P 13 P 4 P(m) 1 chaperone with DnaK; heat shock protein Cell processes b0029 lytB 1331 P 16 P 2 0 control of stringent response; involved in penicillin tolerance Global functions b0032 carA 9312 P 14 P 8 0 carbamoyl-phosphate synthetase, glutamine (small) subunit Metabolism of small molecules b0033 carB 7656 P 48 P 17 0 carbamoyl-phosphate synthase large subunit Metabolism of small molecules b0048 folA 1588 P 7 P 1 0 dihydrofolate reductase type I; trimethoprim resistance Metabolism of small molecules peptidyl-prolyl cis-trans isomerase (PPIase), involved in maturation of b0053 surA 3825 P 19 P 4 P(m) 1 GenProt outer membrane proteins (1st module) Cell processes b0054 imp 2737 P 42 P 5 P(m) 5 GenProt organic solvent tolerance Cell processes b0071 leuD 4770 P 10 P 9 0 isopropylmalate
    [Show full text]
  • The Influence of Cell Cycle Regulation on Chemotherapy
    International Journal of Molecular Sciences Review The Influence of Cell Cycle Regulation on Chemotherapy Ying Sun 1, Yang Liu 1, Xiaoli Ma 2 and Hao Hu 1,* 1 Institute of Biomedical Materials and Engineering, College of Materials Science and Engineering, Qingdao University, Qingdao 266071, China; [email protected] (Y.S.); [email protected] (Y.L.) 2 Qingdao Institute of Measurement Technology, Qingdao 266000, China; [email protected] * Correspondence: [email protected] Abstract: Cell cycle regulation is orchestrated by a complex network of interactions between proteins, enzymes, cytokines, and cell cycle signaling pathways, and is vital for cell proliferation, growth, and repair. The occurrence, development, and metastasis of tumors are closely related to the cell cycle. Cell cycle regulation can be synergistic with chemotherapy in two aspects: inhibition or promotion. The sensitivity of tumor cells to chemotherapeutic drugs can be improved with the cooperation of cell cycle regulation strategies. This review presented the mechanism of the commonly used chemotherapeutic drugs and the effect of the cell cycle on tumorigenesis and development, and the interaction between chemotherapy and cell cycle regulation in cancer treatment was briefly introduced. The current collaborative strategies of chemotherapy and cell cycle regulation are discussed in detail. Finally, we outline the challenges and perspectives about the improvement of combination strategies for cancer therapy. Keywords: chemotherapy; cell cycle regulation; drug delivery systems; combination chemotherapy; cancer therapy Citation: Sun, Y.; Liu, Y.; Ma, X.; Hu, H. The Influence of Cell Cycle Regulation on Chemotherapy. Int. J. 1. Introduction Mol. Sci. 2021, 22, 6923. https:// Chemotherapy is currently one of the main methods of tumor treatment [1].
    [Show full text]
  • The Role of Sumoylation of DNA Topoisomerase Iiα C-Terminal Domain in the Regulation of Mitotic Kinases In
    SUMOylation at the centromere: The role of SUMOylation of DNA topoisomerase IIα C-terminal domain in the regulation of mitotic kinases in cell cycle progression. By Makoto Michael Yoshida Submitted to the graduate degree program in the Department of Molecular Biosciences and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. ________________________________________ Chairperson: Yoshiaki Azuma, Ph.D. ________________________________________ Roberto De Guzman, Ph.D. ________________________________________ Kristi Neufeld, Ph.D. _________________________________________ Berl Oakley, Ph.D. _________________________________________ Blake Peterson, Ph.D. Date Defended: July 12, 2016 The Dissertation Committee for Makoto Michael Yoshida certifies that this is the approved version of the following dissertation: SUMOylation at the centromere: The role of SUMOylation of DNA topoisomerase IIα C-terminal domain in the regulation of mitotic kinases in cell cycle progression. ________________________________________ Chairperson: Yoshiaki Azuma, Ph.D. Date approved: July 12, 2016 ii ABSTRACT In many model systems, SUMOylation is required for proper mitosis; in particular, chromosome segregation during anaphase. It was previously shown that interruption of SUMOylation through the addition of the dominant negative E2 SUMO conjugating enzyme Ubc9 in mitosis causes abnormal chromosome segregation in Xenopus laevis egg extract (XEE) cell-free assays, and DNA topoisomerase IIα (TOP2A) was identified as a substrate for SUMOylation at the mitotic centromeres. TOP2A is SUMOylated at K660 and multiple sites in the C-terminal domain (CTD). We sought to understand the role of TOP2A SUMOylation at the mitotic centromeres by identifying specific binding proteins for SUMOylated TOP2A CTD. Through affinity isolation, we have identified Haspin, a histone H3 threonine 3 (H3T3) kinase, as a SUMOylated TOP2A CTD binding protein.
    [Show full text]
  • Ciprofloxacin Stress Proteome of the Extended-Spectrum Beta-Lactamase
    Ciprofloxacin stress proteome of the extended-spectrum beta-lactamase producing Escherichia coli from slaughtered pigs Sónia Ramos, Ingrid Chafsey, Michel Hébraud, Margarida Sousa, Patrícia Poeta, Gilberto Igrejas To cite this version: Sónia Ramos, Ingrid Chafsey, Michel Hébraud, Margarida Sousa, Patrícia Poeta, et al.. Ciprofloxacin stress proteome of the extended-spectrum beta-lactamase producing Escherichia coli from slaughtered pigs. Current Proteomics, Bentham Science Publishers, 2016, 13, pp.285-289. 10.2174/1570164613666161018144215. hal-01602438 HAL Id: hal-01602438 https://hal.archives-ouvertes.fr/hal-01602438 Submitted on 27 May 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Send Orders for Reprints to [email protected] Current Proteomics, 2016, 13, 1-5 1 RESEARCH ARTICLE Ciprofloxacin Stress Proteome of the Extended-Spectrum -lactamase Producing Escherichia coli from Slaughtered Pigs Sónia Ramos1,2,3,4, Ingrid Chafsey5, Michel Hébraud5,6, Margarida Sousa1,2,3,4, Patrícia Poeta4,7 and Gilberto Igrejas1,2,7,* 1Functional Genomics
    [Show full text]
  • A Protein Kinase Activity Tightly Associated with Drosophila Type II
    Proc. Nati. Acad. Sci. USA Vol. 81, pp. 6938-6942, November 1984 Biochemistry A protein kinase activity tightly associated with Drosophila type II DNA topoisomerase (eukaryotic topoisomerase/protein phosphorylation/Drosophila melanogaster) MIRIAM SANDER, JAMES M. NOLAN, AND TAO-SHIH HSIEH Department of Biochemistry, Duke University Medical Center, Durham, NC 27710 Communicated by Robert L. Hill, July 19, 1984 ABSTRACT A protein kinase activity has been identified tial gene. The mechanism by which the eukaryotic topoiso- that is tightly associated with the purified Drosophila type II merase activities are regulated is not yet clear. Since varia- DNA topoisomerase. The kinase and topoisomerase activities tions in chromatin structure are associated with the are not separated when the enzyme is subjected to analytical processes of transcription, replication, and cell division, it is chromatography (phosphoceilulose, single-strand DNA aga- likely that topoisomerase-mediated alteration in chromatin rose, and Sephacryl S-300) and analytical glycerol gradient structure will be regulated in a complex manner. sedimentation. These two activities are also inactivated to the Recently, a type I topoisomerase isolated from Novikoff same extent by either heat or N-ethylmaleimide treatment. hepatoma cells has been shown to be a phosphoprotein (15). The evidence, however, does not rule out the possibility that In our studies on Drosophila type II topoisomerase we have the kinase activity resides in a polypeptide other than the to- established that the enzyme isolated from the Kco Drosophi- poisomerase polypeptide. The topoisomerase-associated pro- la cell culture line is present in a phosphorylated form (un- tein kinase activity is not stimulated by Ca21 or cyclic nucleo- published data).
    [Show full text]
  • Direct Control of Type IIA Topoisomerase Activity by a Chromosomally Encoded Regulatory Protein
    Direct control of type IIA topoisomerase activity by a chromosomally encoded regulatory protein Seychelle M. Vos,1,4 Artem Y. Lyubimov,1,5 David M. Hershey,2 Allyn J. Schoeffler,1,6 Sugopa Sengupta,3,7 Valakunja Nagaraja,3 and James M. Berger1,8,9 1Department of Molecular and Cell Biology, 2Deparment of Plant and Microbial Biology, University of California at Berkeley, Berkeley, California 94720, USA; 3Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore 560 012, India Precise control of supercoiling homeostasis is critical to DNA-dependent processes such as gene expression, replication, and damage response. Topoisomerases are central regulators of DNA supercoiling commonly thought to act independently in the recognition and modulation of chromosome superstructure; however, recent evidence has indicated that cells tightly regulate topoisomerase activity to support chromosome dynamics, transcriptional response, and replicative events. How topoisomerase control is executed and linked to the internal status of a cell is poorly understood. To investigate these connections, we determined the structure of Escherichia coli gyrase, a type IIA topoisomerase bound to YacG, a recently identified chromosomally encoded inhibitor protein. Phylogenetic analyses indicate that YacG is frequently associated with coenzyme A (CoA) production enzymes, linking the protein to metabolism and stress. The structure, along with supporting solution studies, shows that YacG represses gyrase by sterically occluding the principal DNA-binding site of the enzyme. Unexpectedly, YacG acts by both engaging two spatially segregated regions associated with small-molecule inhibitor interactions (fluoroquinolone antibiotics and the newly reported antagonist GSK299423) and remodeling the gyrase holoenzyme into an inactive, ATP-trapped configuration.
    [Show full text]
  • Structural Basis for the Allosteric Regulation of Human Topoisomerase 2Α
    bioRxiv preprint doi: https://doi.org/10.1101/2020.08.23.263558; this version posted August 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Structural basis for the allosteric regulation of Human Topoisomerase 2α 2 Authors: Arnaud Vanden Broeck 1, 2, Christophe Lotz 1, 2, Robert Drillien 1, 2, Claire Bedez 1, 2 & 3 Valérie Lamour 1, 2, 3 * 4 1 Université de Strasbourg, CNRS, INSERM, Institut de Génétique et de Biologie Moléculaire et Cellulaire 5 (IGBMC), UMR 7104, U1258, IllkircH, France 6 2 Department of Integrated Structural Biology, IGBMC, 1 Rue Laurent Fries, 67404, IllkircH Cedex, France 7 3 Hôpitaux Universitaires de Strasbourg, 1 Place de l’Hôpital, 67091, Strasbourg Cedex, France 8 * Correspondence to Valérie Lamour, [email protected] 9 10 Abstract 11 The human type IIA topoisomerases (Top2) are essential enzymes that regulate DNA topology and 12 chromosome organization. The Top2a isoform is a prime target for antineoplastic compounds used in 13 cancer therapy that form ternary cleavage complexes with the DNA. Despite extensive studies, 14 structural information on this large dimeric assembly is limited to the catalytic domains, hindering the 15 exploration of allosteric mechanism governing the enzyme activities and the contribution of its non- 16 conserved C-terminal domain (CTD). Herein we present cryo-EM structures of the entire human 17 Top2α nucleoprotein complex in different conformations solved at subnanometer resolutions. Our data 18 unveils the molecular determinants that fine tune the allosteric connections between the ATPase 19 domain and the DNA binding/cleavage domain.
    [Show full text]
  • Trapping of the Transport-Segment DNA by the Atpase Domains of a Type II Topoisomerase
    ARTICLE DOI: 10.1038/s41467-018-05005-x OPEN Trapping of the transport-segment DNA by the ATPase domains of a type II topoisomerase Ivan Laponogov1,2,3, Xiao-Su Pan2, Dennis A. Veselkov1, Galyna B. Skamrova1, Trishant R. Umrekar 1,4, L. Mark Fisher 2 & Mark R. Sanderson 1 Type II topoisomerases alter DNA topology to control DNA supercoiling and chromosome segregation and are targets of clinically important anti-infective and anticancer therapeutics. 1234567890():,; They act as ATP-operated clamps to trap a DNA helix and transport it through a transient break in a second DNA. Here, we present the first X-ray crystal structure solved at 2.83 Å of a closed clamp complete with trapped T-segment DNA obtained by co-crystallizing the ATPase domain of S. pneumoniae topoisomerase IV with a nonhydrolyzable ATP analogue and 14-mer duplex DNA. The ATPase dimer forms a 22 Å protein hole occupied by the kinked DNA bound asymmetrically through positively charged residues lining the hole, and whose mutagenesis impacts the DNA decatenation, DNA relaxation and DNA-dependent ATPase activities of topo IV. These results and a side-bound DNA-ParE structure help explain how the T-segment DNA is captured and transported by a type II topoisomerase, and reveal a new enzyme–DNA interface for drug discovery. 1 Randall Centre for Cell and Molecular Biophysics, 3rd Floor New Hunt’s House, Faculty of Life Sciences and Medicine, King’s College London, London SE1 1UL, UK. 2 Molecular and Clinical Sciences Research Institute, St. George’s, University of London, Cranmer Terrace, London SW17 0RE, UK.
    [Show full text]
  • Challenges of Antibacterial Discovery Lynn L
    CLINICAL MICROBIOLOGY REVIEWS, Jan. 2011, p. 71–109 Vol. 24, No. 1 0893-8512/11/$12.00 doi:10.1128/CMR.00030-10 Copyright © 2011, American Society for Microbiology. All Rights Reserved. Challenges of Antibacterial Discovery Lynn L. Silver* LL Silver Consulting, LLC, 955 S. Springfield Ave., Unit C403, Springfield, New Jersey 07081 INTRODUCTION .........................................................................................................................................................72 The Discovery Void...................................................................................................................................................72 Class Modifications versus Novel Classes.............................................................................................................72 BACKGROUND............................................................................................................................................................72 Early Screening—a Brief and Biased Philosophical History .............................................................................72 The Rate-Limiting Steps of Antibacterial Discovery ...........................................................................................74 The Multitarget Hypothesis ....................................................................................................................................74 ANTIBACTERIAL RESISTANCE ..............................................................................................................................75
    [Show full text]
  • Molecular Pathways for Repair of Topoisomerase II - Mediated DNA Damage
    Molecular Pathways for Repair of Topoisomerase II - Mediated DNA Damage BY YILUN SUN B.Sc. Pharmaceutical Sciences, Capital Medical University, 2010 M.Sc. Biotechnology, Georgetown University, 2012 THESIS Submitted as partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biopharmaceutical Sciences in the Graduate College of the University of Illinois at Chicago, 2017 Chicago, Illinois Defense Committee: John L. Nitiss, PhD, Chair and Advisor William T. Beck, PhD, Debra A. Tonetti, PhD, Alexander S. Mankin, PhD, Medicinal Chemistry and Pharmacognosy Jie Liang, PhD, Bioengineering ACKNOWLEDGEMENTS I would like to thank Dr. John Nitiss for offering me the opportunity to work on this research project. I owe this work to Dr. John Nitiss, as he has fostered me from the beginning by helping me expand my knowledge and gain an aptitude for research. I would also like to express my gratitude to Dr. Karin Nitiss. Without her guidance, teaching and support, I could not complete this project. It has been an honor and pleasure for me to work in the Nitiss lab and learn everything from them. I would also like to extend my appreciation to all those who have helped me at any point in my research, especially my thesis committee members: Dr. William Beck, Dr. Alexander Mankin, Dr. Debra Tonetti, and Dr. Jie Liang. I sincerely appreciate their invaluable insight, comments and encouragement. I would like to thank my colleagues Jay Anand and Matt Gilbertson for making the Nitiss lab a great place to work. At last, I would like to thank my parents and my wife for their all kinds of support.
    [Show full text]
  • Topoisomerase VI Participates in an Insulator-Like Function That Prevents H3k9me2 Spreading Into Euchromatic Islands
    bioRxiv preprint doi: https://doi.org/10.1101/829416; this version posted November 4, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Topoisomerase VI participates in an insulator-like function that prevents H3K9me2 spreading into euchromatic islands Louis-Valentin Méteignier1, Cécile Lecampion1, Florent Velay1, Cécile Vriet1,2, Laura Dimnet1, Michel Térèse3, Martin Rougée4,5, Christian Breuer6, Ludivine Soubigou-Taconnat7,8, Keiko Sugimoto6, Fredy Barneche4,5 and Christophe Laloi 1*. 1Aix Marseille Univ, CEA, CNRS, BIAM, Marseille, France F-13009 2UMR CNRS 7267, University of Poitiers, 86073 Poitiers Cedex 3Independent informatician, 06100 Nice, France 4IBENS, Département de Biologie, Ecole Normale Supérieure, CNRS, PSL Research University, F- 75005, Paris, France 5Université Paris-Sud, Université Paris-Saclay, 91405, Orsay, France 6RIKEN Center for Sustainable Resource Science, Yokohama, 230-0045, Japan 7Institute of Plant Sciences Paris Saclay IPS2, CNRS, INRA, Université Paris-Sud, Université Evry, Université Paris-Saclay, Bâtiment 630, 91405 Orsay, France. 8Institute of Plant Sciences Paris-Saclay IPS2, Paris Diderot, Sorbonne Paris-Cité, Bâtiment 630, 91405, Orsay, France Keywords Euchromatin islands / Heterochromatin spreading / Insulator / Methionine Adenosyltransferase / Topoisomerase VI. 1 bioRxiv preprint doi: https://doi.org/10.1101/829416; this version posted November 4, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract The organization of the genome into transcriptionally active and inactive chromatin domains requires well-delineated chromatin boundaries and insulator functions in order to maintain the identity of adjacent genomic loci with antagonistic chromatin marks and functionality.
    [Show full text]
  • Topoisomerase II Expression in Breast Cancer
    Topoisomerase II␣ Expression in Breast Cancer: Correlation with Outcome Variables Peter L. Depowski, M.D., Seth I. Rosenthal, M.D., Thomas P. Brien, M.D., Scott Stylos, M.D., Rebecca L. Johnson, M.D., Jeffrey S. Ross, M.D. Department of Pathology, Albany Medical College (PLD, SIR, TPB, JSR), Albany, New York, and Berkshire Medical Center (SS, RLJ), Pittsfield, Massachusetts iate analysis, stage (p < .0001), lymph node metas- all (002. ؍ Topoisomerase II␣ (topo II␣) plays a key role in tasis (p < .0001), and tumor grade (p DNA replication and is a target for multiple chemo- independently predicted disease-related death. therapeutic agents. In breast cancer, topo II expres- Increased topo II expression is associated with an sion has been linked to cell proliferation and HER2/ aggressive form of breast cancer featuring HER-2 neu protein overexpression. However, its amp and predicts disease-related death, lymph relationship with outcome variables is not well es- node metastasis, and advanced tumor stage. tablished. Formalin-fixed, paraffin-embedded primary KEY WORDS: Breast cancer, HER-2/neu, MIB-1, breast cancers from 184 women (mean age, 60 Stage, Survival, Topoisomerase II␣ years) were stained for topo II by automated immu- Mod Pathol 2000;13(5):542–547 nohistochemistry. A topo II expression index (TI) was determined by counting the number of positive Topoisomerase II␣ (topo II␣) is a component of the cells per high-power field and calculating an overall DNA machinery that is intricately involved at many mean number of positive cells per high-power field. levels of DNA metabolism (1–3). Its primary func- Tumors with a TI of more than 1 were considered tion is to alter DNA topology from its storage (su- positive, and those with a TI of 1 or less were con- percoiled) form to a more exposed (partially un- sidered negative.
    [Show full text]